Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

BACKGROUND: Increased risk of cardiovascular events is associated not only with dyslipidemias, but also with abnormalities in glucose metabolism and liver function. This study uses pooled analysis to explore the in-depth effects of pemafibrate, a selective peroxisome proliferator-activated receptor...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cardiovasc Diabetol
Hoofdauteurs: Yokote, Koutaro, Yamashita, Shizuya, Arai, Hidenori, Araki, Eiichi, Matsushita, Mitsunori, Nojima, Toshiaki, Suganami, Hideki, Ishibashi, Shun
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2021
Onderwerpen:
Original Investigation
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8097867/
https://ncbi.nlm.nih.gov/pubmed/33947390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01291-w
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items